WallStSmart

Abbott Laboratories (ABT)vsNovocure Ltd (NVCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 6592% more annual revenue ($45.13B vs $674.41M). ABT leads profitability with a 13.9% profit margin vs -25.7%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

NVCR

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
NVCRUndervalued (+81.5%)

Margin of Safety

+81.5%

Fair Value

$56.90

Current Price

$17.16

$39.74 discount

UndervaluedFair: $56.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

NVCR0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

NVCR4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-52.3%2/10

ROE of -52.3% — below average capital efficiency

EPS GrowthGrowth
-6.0%2/10

Earnings declined 6.0%

Free Cash FlowQuality
$-18.67M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : NVCR

Revenue growth of 12.3% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : NVCR

The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ABT profiles as a value stock while NVCR is a turnaround play — different risk/reward profiles.

NVCR carries more volatility with a beta of 0.92 — expect wider price swings.

NVCR is growing revenue faster at 12.3% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 29/100). NVCR offers better value entry with a 81.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Novocure Ltd

HEALTHCARE · MEDICAL DEVICES · USA

NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.

Want to dig deeper into these stocks?